A Phase II multicenter, open-label, randomized, parallel group, study of MPC-4326 [bevirimat] in HIV-1 positive patients to evaluate the safety, efficacy, and pharmacokinetics of MPC-4326 administered as monotherapy for 14 days and as part of an optimized background regimen for up to 72 weeks.

Trial Profile

A Phase II multicenter, open-label, randomized, parallel group, study of MPC-4326 [bevirimat] in HIV-1 positive patients to evaluate the safety, efficacy, and pharmacokinetics of MPC-4326 administered as monotherapy for 14 days and as part of an optimized background regimen for up to 72 weeks.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Bevirimat (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Myrexis
  • Most Recent Events

    • 07 Jan 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 07 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Nov 2009 Myriad Pharmaceuticals added as trial sponsor and affiliate as reported by Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top